179
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Proteomic profile of serum of pregnant women carring a fetus with Down syndrome using nano uplc Q-tof ms/ms technology

, , , , , & show all
Pages 1483-1489 | Received 29 Aug 2016, Accepted 12 Apr 2017, Published online: 03 May 2017

References

  • Hook EB. Ultrasound and fetal chromosome abnormalities. Lancet. 1992;340:1109.
  • Presson AP, Partyka G, Jensen KM, et al. Current estimate of Down syndrome population prevalence in the United States. J Pediatr. 2013;163:1163–1168.
  • Mutchinick O, Lisker R, Babinsky V. Riesgo para síndrome de Down por bienios y quinquenios de edad materna en la población mexicana. Bol Med Hosp Infant Mex. 1991;48:534–537.
  • Hörmansdörfer C, Corral A, Scharf A, et al. Comparación de los métodos actuales de cribado prenatal del síndrome de Down. Rev Esp Salud Pública. 2010;84:43–51.
  • Grether González P, Aguinaga Ríos M. Tamiz genético prenatal: marcadores bioquímicos del primer y segundo trimestres. Ginecol Obstet Mex. 2009;77:S27–S46.
  • Malone FD, Canick JA, Ball RH, et al. First and second trimester evaluation of risk (FASTER) Research Consortium. First-trimester or second trimester screening, or both, for Down’s syndrome. N Engl J Med. 2005;353:2001–2011.
  • Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485–487.
  • Loman NJ, Constantinidou C, Chan JZ, et al. High-throughput bacterial genome sequencing: an embarrassment of choice, a world of opportunity. Nat Rev Microbiol. 2012;10:599–606.
  • Devers PL, Cronister A, Ormond KE, et al. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Counsel. 2013;22:291–295.
  • Gekas J, Langlois S, Ravitsky V, et al. Identification of trisomy 18, trisomy 13, and Down syndrome from maternal plasma. Appl Clin Genet. 2014;7:127–131.
  • Pennings JL, Koster MP, Rodenburg W, et al. Discovery of novel serum biomarkers for prenatal Down syndrome screening by integrative data mining. PLoS One. 2009;4:1–6.
  • Nagalla SR, Canick JA, Jacob T, et al. Proteomic analysis of maternal serum in Down syndrome: identification of novel protein biomarkers. J Proteome Res. 2007;6:1245–1257.
  • Kolialexi A, Tsangaris GT, Papantoniou N, et al. Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma. Prenat Diagn. 2008;28:691–698.
  • Koster MP, Pennings JL, Imholz S, et al. Bread-based multiplexed inmunoassays to identify new biomarkers in maternal serum to improve first trimester Down syndrome screening. Prenat Diagn. 2009;29:857–862.
  • Kang Y, Dong X, Zhou Y, et al. Identification of novel candidate maternal serum protein markers for Down syndrome by integrated proteomic and bioinformatic analysis. Prenat Diagn. 2012;32:284–292.
  • Yu B, Zhang B, Wang J, et al. Preliminary proteomic-based identification of a novel protein for Down's syndrome in maternal serum. Exp Biol Med (Maywood). 2012;237:530–539.
  • Avent ND. Maternal plasma biomarkers for Down syndrome: present and future. Drugs Today. 2013;49:145–152.
  • Narasimhan K, Lin SL, Tong T, et al. Maternal serum protein profile and immune response protein subunits as markers for non-invasive prenatal diagnosis of trisomy 21, 18, and 13. Prenat Diagn. 2013;33:223–231.
  • Barch MJ, Knutsen T, Spurbeck JL. The AGT cytogenetics laboratory manual. 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1997. p. 199–258.
  • Wang TH, Chao AS, Chen JK, et al. Network analyses of differentially expressed proteins in amniotic fluid supernatant associated with abnormal human karyotypes. Fertil Steril. 2009;92:96–107.
  • Ishihara K. Identification of molecules with altered expression in the brain of mouse model for Down syndrome by comprehensive analyses. Yakugaku Zasshi. 2013;133:989–994.
  • Di Domenico F, Pupo G, Tramutola A, et al. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radic Biol Med. 2014;71:270–280.
  • Gardiner K, Costa AC. The proteins of human chromosome 21. Am J Med Genet C Semin Med Genet. 2006;142C:196–205.
  • Rachidi M, Lopes C. Molecular and cellular mechanisms elucidating neurocognitive basis of functional impairments associated with intellectual disability in Down syndrome. Am J Intellect Dev Disabil. 2010;115:83–112.
  • Derzsy Z, Prohászka Z, Rigó Jra J, et al. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol. 2010;47:1500–1506.
  • Sailer T, Zoghlami C, Kurz C, et al. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost. 2006;95:796–801.
  • Rull K, Nagirnaja L, Laan M. Genetics of recurrent miscarriage: challenges, current knowledge, future directions. Front Genet. 2012;3:1–13.
  • Wang Y, Mulligan C, Denyer G, et al. Quantitative proteomics characterization of a mouse embryonic stem cell model of Down syndrome. Mol Cell Proteomics. 2009;8:585–595.
  • Di Domenico F, Coccia R, Cocciolo A, et al. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta. 2013;1832:1249–1259.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.